MX 68

Drug Profile

MX 68

Latest Information Update: 19 Sep 2006

Price : $50

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharma Europe; Chugai Pharmaceutical
  • Class Antirheumatics
  • Mechanism of Action Immunosuppressants; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 19 Sep 2006 Discontinued - Phase-I for Rheumatoid arthritis in United Kingdom (PO)
  • 19 Sep 2006 Discontinued - Preclinical for Rheumatoid arthritis in Japan (unspecified route)
  • 01 Nov 2002 Chugai Pharmaceutical has been acquired by Roche
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top